CFS
ACRS icon

CRA Financial Services’s Aclaris Therapeutics ACRS Stock Holding History

CRA Financial Services’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66.7K Hold
17,782
– – 0.01% 293
2025
Q4 		$53.5K Hold
17,782
– – 0.01% 289
2025
Q3 		$33.8K Hold
17,782
– – ﹤0.01% 293
2025
Q2 		$25.3K Buy
+17,782
New +$24.1K ﹤0.01% 276

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CRA Financial Services's ACRS Position: Q1 2026 in Review

CRA Financial Services held its Aclaris Therapeutics (ACRS) position steady in Q1 2026 at 17,782 shares worth $66.7K. The position accounts for 0.01% of the portfolio, ranked #293.

CRA Financial Services first reported a position in ACRS in Q2 2025 and has held it in 4 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • CRA Financial Services held 17,782 shares of Aclaris Therapeutics worth $66.7K as of Q1 2026.
  • CRA Financial Services left its Aclaris Therapeutics share count unchanged in Q1 2026.
  • Aclaris Therapeutics made up 0.01% of CRA Financial Services's portfolio in Q1 2026, its #293 holding.
  • CRA Financial Services first reported a position in Aclaris Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on CRA Financial Services's 13F filing for Q1 2026, filed 9 Apr 2026.